UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 112

Sortiert nach

Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer

Annals of oncology, 2018-12, Vol.29 (12), p.2334-2340

2018

Volltextzugriff (PDF)

Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation

British journal of cancer, 2023-06, Vol.128 (11), p.2072-2080

2023

Volltextzugriff (PDF)

Pharmacogenomic predictor of long-term residual chemotherapy-induced peripheral neuropathy in ovarian cancer survivors: A substudy of the GINECO Vivrovaire study

Gynecologic oncology, 2024-08, Vol.187, p.139-144

2024

Volltextzugriff (PDF)

Enrollment of older metastatic breast cancer patients in first-line clinical trials: 9-year experience of the large-scale real-life multicenter French ESME cohort

Breast cancer research and treatment, 2022-02, Vol.191 (3), p.577-587

2022

Volltextzugriff (PDF)

5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study

European journal of cancer (1990), 2018-05, Vol.95, p.30-37

2018

Volltextzugriff (PDF)

Association between post-operative hPG80 (circulating progastrin) detectable level and worse prognosis in glioblastoma

ESMO open, 2023-10, Vol.8 (5), p.101626-101626, Article 101626

2023

Volltextzugriff (PDF)

Management and outcome of metastatic breast cancer in men in the national multicenter observational ESME program

Annals of oncology, 2018-10, Vol.29, p.viii710-viii710

2018

Volltextzugriff (PDF)

Bcl-2 proteins expression and response to navitoclax in platinum resistant/refractory recurrent ovarian cancer (PROC)

Annals of oncology, 2018-10, Vol.29, p.viii347-viii347

2018

Volltextzugriff (PDF)

EXPRESS study: A multicenter, prospective trial in progress exploring the association between low level of genomic alteration and exceptional and unexpected response to targeted therapies in patients with solid tumors

Annals of oncology, 2018-10, Vol.29, p.viii57-viii57

2018

Volltextzugriff (PDF)

Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial

Annals of oncology, 2022-10, Vol.33 (10), p.1021-1028

2022

Volltextzugriff (PDF)

Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience

Journal of neuro-oncology, 2013-08, Vol.114 (1), p.85-91

2013

Volltextzugriff (PDF)

Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas

British journal of cancer, 2008-06, Vol.98 (12), p.1993-1998

2008

Volltextzugriff (PDF)

Medical oncologists must get more involved in systemic treatment of hepatocellular carcinoma

Annals of oncology, 2019-01, Vol.30 (1), p.6-8

2019

Volltextzugriff (PDF)

Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series

Annals of oncology, 2013-04, Vol.24 (4), p.916-924

2013

Volltextzugriff (PDF)

Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohort

ESMO open, 2024-05, Vol.9 (5), p.103447-103447, Article 103447

2024

Volltextzugriff (PDF)

Concerns of young women with breast cancer and theirs partners from chemotherapy to follow-up: a cross-sectional study

Annals of oncology, 2016-10, Vol.27, p.vi513-vi513

2016

Volltextzugriff (PDF)

Prognostic factors for patients treated for a recurrent FIGO stage III ovarian cancer: A retrospective study of 108 cases

European journal of surgical oncology, 2011-11, Vol.37 (11), p.971-977

2011

Volltextzugriff (PDF)

Recent trends in breast cancer incidence rates in the Loire-Atlantique, France: A decline since 2003

Cancer epidemiology, 2010-06, Vol.34 (3), p.238-243

2010

Volltextzugriff (PDF)

Lapatinib in metastatic breast cancer

Women's health (London, England), 2009-11, Vol.5 (6), p.603-612

2009

Volltextzugriff (PDF)

Characteristics of IDH-mutant gliomas with non-canonical IDH mutation

Journal of neuro-oncology, 2021, Vol.151 (2), p.279-286

2021

Volltextzugriff (PDF)

803P An histopathological algorithm to help the search for POLE mutated endometrial cancers

Annals of oncology, 2021-09, Vol.32, p.S763-S764

2021

Volltextzugriff (PDF)

156P Impact of HER2 status (HER2-low versus HER2-0) on complete histologic response after neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC)

Annals of oncology, 2021-09, Vol.32, p.S428-S429

2021

Volltextzugriff (PDF)

Medical oncologists must get more involved in systemic treatment

Annals of oncology, 2019-01, Vol.30 (1), p.6-8

2019

Volltextzugriff (PDF)

478P Metronomic oral vinorelbine (MOV) combined with tremelimumab (T) + durvalumab (D): Results of the tumor mutational burden-high (TMB-h) and/or microsatellite instability-high (MSI-h) cohort of the MOVIE study

Annals of oncology, 2022-09, Vol.33, p.S758-S759

2022

Volltextzugriff (PDF)

1 – 25 von 112

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(101)
Mit Volltextzugriff
(106)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer

Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation

Pharmacogenomic predictor of long-term residual chemotherapy-induced peripheral neuropathy in ovarian cancer survivors: A substudy of the GINECO Vivrovaire study

Enrollment of older metastatic breast cancer patients in first-line clinical trials: 9-year experience of the large-scale real-life multicenter French ESME cohort

Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer

5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study

Association between post-operative hPG80 (circulating progastrin) detectable level and worse prognosis in glioblastoma

Management and outcome of metastatic breast cancer in men in the national multicenter observational ESME program

Bcl-2 proteins expression and response to navitoclax in platinum resistant/refractory recurrent ovarian cancer (PROC)

EXPRESS study: A multicenter, prospective trial in progress exploring the association between low level of genomic alteration and exceptional and unexpected response to targeted therapies in patients with solid tumors

Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial

Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience

Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas

Medical oncologists must get more involved in systemic treatment of hepatocellular carcinoma

Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series

Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohort

Concerns of young women with breast cancer and theirs partners from chemotherapy to follow-up: a cross-sectional study

Prognostic factors for patients treated for a recurrent FIGO stage III ovarian cancer: A retrospective study of 108 cases

Recent trends in breast cancer incidence rates in the Loire-Atlantique, France: A decline since 2003

Lapatinib in metastatic breast cancer

Characteristics of IDH-mutant gliomas with non-canonical IDH mutation

803P An histopathological algorithm to help the search for POLE mutated endometrial cancers

156P Impact of HER2 status (HER2-low versus HER2-0) on complete histologic response after neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC)

Medical oncologists must get more involved in systemic treatment

478P Metronomic oral vinorelbine (MOV) combined with tremelimumab (T) + durvalumab (D): Results of the tumor mutational burden-high (TMB-h) and/or microsatellite instability-high (MSI-h) cohort of the MOVIE study

Suchergebnisse filtern